Quality-of-Life Instruments: Evaluation of the Impact of Psoriasis on Patients

Dermatologic Clinics

Volumn 30, Issue 2, 2012, Pages 281-291

  Heller, Misha M ^a,b   Wong, Jillian W ^a,c   Nguyen, Tien V ^a,d   Lee, Eric S ^a,e   Bhutani, Tina ^a   Menter, Alan ^f,g   Koo, John Y M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e NEBRASKA MEDICAL CENTER   (United States)

^f BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Biologics; Psoriasis; Psoriasis treatments; Quality of life instruments

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; METHOTREXATE; STELERA; UNCLASSIFIED DRUG; USTEKINUMAB;

CHILDREN DERMATOLOGY LIFE QUALITY INDEX; CLINICAL ASSESSMENT TOOL; DERMATOLOGY LIFE QUALITY INDEX; DERMATOLOGY QUALITY OF LIFE SCALES; DERMATOLOGY SPECIFIC QUALITY OF LIFE; HUMAN; KOO MENTER PSORIASIS INSTRUMENT; PATIENT ATTITUDE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS DISABILITY INDEX; PSORIASIS INDEX OF QUALITY OF LIFE; PSORIASIS LIFE STRESS INVENTORY; PSORIASIS QUALITY OF LIFE 12 ITEMS; PSYCHOLOGICAL GENERAL WELL BEING INDEX; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SALFORD PSORIASIS INDEX; SHORT FORM 36; SICKNESS IMPACT PROFILE; SKINDEX; SOCIAL BEHAVIOR; WELLBEING;

HEALTH STATUS; HUMANS; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRES; STRESS, PSYCHOLOGICAL; TREATMENT OUTCOME;

EID: 84856245789     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2011.11.006     Document Type: Review

References (45)

1. National Psoriasis Foundation. About psoriasis: statistics. Available at: Accessed July 15, 2011. http://www.psoriasis.org/netcommunity/learn/about-psoriasis/statistics.
2. de Korte J., Sprangers M.A., Mombers F.M., et al. Quality of life in patients with psoriasis: a systematic literature review. JInvestig Dermatol Symp Proc 2004, 9:140-147.
3. Gupta M.A., Gupta A.K., Kirkby S., et al. A psychocutaneous profile of psoriasis patients who are stress reactors. A study of 127 patients. Gen Hosp Psychiatry 1989, 11:166-173.
4. Gupta M.A., Gupta A.K. Quality of life of psoriasis patients. JEur Acad Dermatol Venereol 2000, 14:241-242.
5. Gupta N. Comorbid disease in psoriasis. Don't forget mental illnesses. BMJ 2010, 340:c781.
6. Russo P.A., Ilchef R., Cooper A.J. Psychiatric morbidity in psoriasis: a review. Australas J Dermatol 2004, 45:155-159. [quiz: 60-1].
7. National Psoriasis Foundation. 2009 survey panel results. Available at: Accessed July 15, 2011. http://www.psoriasis.org/page.aspx%3Fpid%3d668.
8. Rapp S.R., Feldman S.R., Exum M.L., et al. Psoriasis causes as much disability as other major medical diseases. JAm Acad Dermatol 1999, 41:401-407.
9. Walker C., Papadopoulos L. Psychodermatology 2005, Cambridge University Press, Cambridge (NY).
10. Koo J.Y., Lee C.S. Psychocutaneous medicine 2003, Marcel Dekker, New York.
11. Harth W. Clinical management in psychodermatology 2008, Springer, New York. 1st edition.
12. Lewis V.J., Finlay A.Y. Acritical review of Quality-of-Life Scales for Psoriasis. Dermatol Clin 2005, 23:707-716.
13. Jenkinson C., Coulter A., Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ 1993, 306:1437-1440.
14. Garratt A.M., Ruta D.A., Abdalla M.I., et al. The SF36 health survey questionnaire: an outcome measure suitable for routine use within the NHS?. BMJ 1993, 306:1440-1444.
15. Bergner M., Bobbitt R.A., Carter W.B., et al. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981, 19:787-805.
16. Goldberg D.P., Hillier V.F. Ascaled version of the General Health Questionnaire. Psychol Med 1979, 9:139-145.
17. Dupuy H. The Psychological General Well-Being (PGWB) Index. Assessment of quality of life in clinical trials of cardiovascular therapies 1984, 170-183. Le Jacq Publishing, Washington. N. Wenger, M. Mattson, C. Furberg (Eds.).
18. Finlay A.Y., Khan G.K. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994, 19:210-216.
19. Lewis V., Finlay A.Y. 10 years experience of the Dermatology Life Quality Index (DLQI). JInvestig Dermatol Symp Proc 2004, 9:169-180.
20. Morgan M., McCreedy R., Simpson J., et al. Dermatology quality of life scales: a measure of the impact of skin diseases. Br J Dermatol 1997, 136:202-206.
21. Anderson R.T., Rajagopalan R. Development and validation of a quality of life instrument for cutaneous diseases. JAm Acad Dermatol 1997, 37:41-50.
22. Chren M.M., Lasek R.J., Quinn L.M., et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. JInvest Dermatol 1996, 107:707-713.
23. Lewis-Jones M.S., Finlay A.Y. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 1995, 132:942-949.
24. Holme S.A., Man I., Sharpe J.L., et al. The Children's Dermatology Life Quality Index: validation of the cartoon version. Br J Dermatol 2003, 148:285-290.
25. Finlay A.Y., Kelly S.E. Psoriasis: an index of disability. Clin Exp Dermatol 1987, 12:8-11.
26. Finlay A.Y., Coles E.C. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995, 132:236-244.
27. Gupta M.A., Gupta A.K. The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress. Acta Derm Venereol 1995, 75:240-243.
28. McKenna S.P., Cook S.A., Whalley D., et al. Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials. Br J Dermatol 2003, 149:323-331.
29. Kirby B., Fortune D.G., Bhushan M., et al. The Salford Psoriasis Index: an holistic measure of psoriasis severity. Br J Dermatol 2000, 142:728-732.
30. Koo J.Y. Moderate-to-severe psoriasis 2009, Informa Healthcare, New York. 3rd edition.
31. Heydendael V.M., de Borgie C.A., Spuls P.I., et al. The burden of psoriasis is not determined by disease severity only. JInvestig Dermatol Symp Proc 2004, 9:131-135.
32. Wallenhammar L.M., Nyfjall M., Lindberg M., et al. Health-related quality of life and hand eczema: a comparison of two instruments, including factor analysis. JInvest Dermatol 2004, 122:1381-1389.
33. Finlay A.Y., Khan G.K., Luscombe D.K., et al. Validation of sickness impact profile and psoriasis disability index in psoriasis. Br J Dermatol 1990, 123:751-756.
34. Root S., Kent G., al-Abadie M.S. The relationship between disease severity, disability and psychological distress in patients undergoing PUVA treatment for psoriasis. Dermatology 1994, 189:234-237.
35. Bhutani T, Patel T, Koo B, et al. A prospective, interventional assessment of psoriasis quality of life utilizing a non-skin specific validated instrument that allows comparison with other major medical conditions. Accepted for Poster Presentation. American Academy of Dermatology's 70th Annual Meeting 2011. San Diego (CA), March 16-20, 2012.
36. Feldman S.R., Menter A., Koo J.Y. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol 2004, 150:317-326.
37. de Jager M.E., van de Kerkhof P.C., de Jong E.M., et al. Across-sectional study using the Children's Dermatology Life Quality Index (CDLQI) in childhood psoriasis: negative effect on quality of life and moderate correlation of CDLQI with severity scores. Br J Dermatol 2010, 163:1099-1101.
38. Zachariae H., Zachariae R., Blomqvist K., et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 2002, 82:108-113.
39. Feldman S.R., Koo J.Y., Menter A., et al. Decision points for the initiation of systemic treatment for psoriasis. JAm Acad Dermatol 2005, 53:101-107.
40. Koo J., Kozma C., Reinke K. The development of a disease-specific questionnaire to assess the quality of life for psoriasis patients: an analysis of the reliability, validity, and responsiveness of the psoriasis quality of life questionnaire. Dermatol Psychosom 2002, 3:171-179.
41. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996, 14:485-496.
42. Koo J.Y., Martin D. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. Int J Dermatol 2001, 40:210-212.
43. Koo J., Menter A., Lebwohl M. The relationship between quality of life and disease severity: results from a large cohort of mild, moderate, and severe psoriasis patients. Br J Dermatol 2002, 147:1078. [abstract].
44. Koo J, Kozma C, Menter A. Development of a disease-specific quality of life questionnaire: the 12-item Psoriasis Quality of Life Questionnaire (PQOL-12). Presented at the 61st Annual Meeting of the American Academy of Dermatology. San Francisco (CA), March 21-26, 2003.
45. Ware J., Harris W., Gandeck B., et al. MAP-R for Windows: Multitrait/Multi-item Analysis Program-Revised User's Guide 1997, Health Assessment Laboratory, Boston.